摘要
目的评价奎硫平联合抗抑郁药物与抗抑郁药物单一治疗抑郁症的差异。方法应用循证医学方法对符合标准的12项研究进行分析,评价奎硫平联合抗抑郁药物与抗抑郁药物单一治疗抑郁症的有效率、痊愈率的差异。结果奎硫平组与对照组的有效率差异具有统计学意义(65.5%vs.45.3%,OR=2.59,95%CI1.88～3.56,Z=5.82,P<0.01),痊愈率的差异也具有统计学意义(34.1%vs.17.0%,OR=2.77,95%CI1.89～4.00,Z=5.15,P<0.01),对难治性抑郁症的痊愈率也显著提高(22.5%vs.3.8%,OR=6.67,95%CI2.34～19.01,Z=3.55,P<0.01)。结论中、小剂量奎硫平联合抗抑郁药物治疗抑郁症是一种良好的方法,可能特别适宜于难治性抑郁症。
Objective To assess the difference between Quetiapine combining antidepressants and single antidepressant in treatment of depression. Methods 12 studies meeting our criteria were analyzed by evidence-based medicine, comparing the difference in efficacy, effect size（ES）, full remission rate and side effects. Results The very significant differences in effective rate and full remission rate were found between two groups（effective rate： 65.5% vs.45.3%,OR=2.59,95%CI 1.88-3.56,Z=5.82,P〈0.01; full remission rate： 34.1%vs. 17.0%, OR=2.77, 95%CI 1.89-4.00,Z=5.15,P〈0.01）. And significant rate of full remission in therapy for treatment-resistant depression in Quetiapine groups was higher than that of control groups （22.5%vs.3.8%,OR=6.67,95%CI 2.34-19.01,Z=3.55,P〈 0.01）. Conclusion It is a better therapy for patients with depression, especially treatment-resistant depression, combining antidepressants with middle or lower dosage of Quetiapine.
出处
《循证医学》
CSCD
2008年第4期224-227,共4页
The Journal of Evidence-Based Medicine
